Hot Features
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia... Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.276243093923 | 3.62 | 3.97 | 3.485 | 2239058 | 3.65121198 | CS |
| 4 | 0.12 | 3.4188034188 | 3.51 | 3.97 | 3.035 | 1977663 | 3.48190113 | CS |
| 12 | -0.94 | -20.5689277899 | 4.57 | 5.29 | 3.035 | 1713097 | 3.91502049 | CS |
| 26 | -0.32 | -8.10126582278 | 3.95 | 6.42 | 2.715 | 2893851 | 4.48592167 | CS |
| 52 | 0.59 | 19.4078947368 | 3.04 | 6.42 | 2.715 | 2427173 | 4.23489492 | CS |
| 156 | 0.32 | 9.66767371601 | 3.31 | 13.68 | 1.61 | 1195144 | 4.61196259 | CS |
| 260 | -5.12 | -58.5142857143 | 8.75 | 15.2581 | 1.53 | 783608 | 4.63279266 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.